Skip to main content

How is pembrolizumab (Keytruda) administered?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Jan 20, 2024.

Official Answer by Drugs.com

Key Points

Pembrolizumab (brand name: Keytruda) is a cancer medicine administered by a slow intravenous (IV) infusion into your vein, usually over a period of at least 30 minutes.

You will most likely receive this treatment in an outpatient clinic or hospital once every 3 or 6 weeks. Your health care provider will give you this medicine. It is important you do not miss your appointments.

This medicine may be administered alone or with other oral or IV treatments, depending upon your treatment plan.

Your doctor will determine the best dose and schedule for you based on the type of cancer or condition being treated, your weight, your health, other treatments, and side effects you may experience, among other factors.

You will continue this medicine until your disease worsens or you have bad side effects that require you to stop treatment. If you do not have disease progression, you would continue for up to 24 months, or possibly longer.

Patients being treated with Keytruda as an adjuvant for melanoma may continue for up to 12 months. Adjuvant therapy is given after primary treatment (such as surgery) to increase the chance of long-term survival.

Your doctor may perform a blood test to make sure pembrolizumab is the right treatment for your condition. You will need other medical tests to check on the safety of this medication and if you can continue treatment. Your doctor will also check how well your liver and kidneys are working.

Which cancers can pembrolizumab (Keytruda) treat?

Pembrolizumab (Keytruda) is an FDA-approved prescription used to treat many different cancers, including:

Pembrolizumab is often given when other cancer treatments stop working or if the cancer has spread to other areas in the body. It may also be an option if the cancer cannot be removed surgically.

Related questions

What kind of drug is pembrolizumab (Keytruda)?

Pembrolizumab (Keytruda) is known as an immune checkpoint inhibitor.

For some cancers, pembrolizumab may be used if your tumor tests positive for programmed death-ligand 1 (PD-L1). Drugs that target these checkpoints are now used to fight many different types of cancer. It may be used in combination with other medicines, as well.

Immune checkpoint inhibitors include:

How long does it take for pembrolizumab (Keytruda) to start working?

You will use pembrolizumab for as long as it works and you are able to tolerate the side effects. Most people use pembrolizumab for up to two years if tolerated and the medicine continues to be effective. Your doctor will decide the best length for your treatment.

Bottom Line

This is not all the information you need to know about pembrolizumab (brand name: Keytruda) for safe and effective use. Review the full product information here, and discuss this information with your doctor or other health care provider.

References

Read next

How is Keytruda used for lung cancer?

Keytruda (pembrolizumab) is a type of immunotherapy that has significantly changed the treatment landscape for lung cancer, especially non-small cell lung cancer (NSCLC). It works by helping the immune system recognize and attack cancer cells more effectively, mainly by blocking the PD-1 pathway that tumors use to evade immune detection.

Continue reading

How effective Is Keytruda for metastatic melanoma?

Keytruda (pembrolizumab) is an immunotherapy known as a PD-1 inhibitor, approved by the FDA for the treatment of unresectable or metastatic melanoma. This therapy has transformed the outlook for many patients with advanced melanoma, offering the potential for extended survival and durable responses in some cases. At 10 years, 34% of patients treated with Keytruda were still alive, compared to 23.6% for those treated with ipilimumab, another immunotherapy.

Continue reading

When is Keytruda used for prostate cancer?

Keytruda (pembrolizumab) is used only for advanced prostate cancer with specific genetic features: microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. This immunotherapy is not a standard prostate cancer treatment but is reserved for biomarker-confirmed cases where other options have failed.

Continue reading

See also:

Related medical questions

Drug information

Related support groups